Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 6/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072735 | 0.89 | BMPR1B (0.39) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL4072727 | 0.86 | KCNH2 (0.45) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL4248782 | 0.86 | KCNH2 (0.45) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL6003397 | 0.86 | KCNH2 (0.45) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL20995219 | 0.84 | BMPR1B (0.42) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| Hydrochloric Acid SCHEMBL5443600 | 0.84 | SLC6A2 (0.44) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL20995218 | 0.84 | BMPR1B (0.42) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL11462222 | 0.84 | SMN1; SMN2 (0.46) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL4180285 | 0.84 | SLC6A2 (0.49) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL4077178 | 0.84 | DRD3 (0.41) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | claimed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | claimed |
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | BMPR1B 361/4885BMPR1A 605/4885TGFBR1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.